Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
Top Cited Papers
Open Access
- 15 March 2013
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 381 (9869), 805-816
- https://doi.org/10.1016/s0140-6736(12)61963-1
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: a randomised controlled trialThe Lancet, 2011
- Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trialsThe Lancet, 2011
- Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus TamoxifenJournal of Clinical Oncology, 2010
- Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 StudyJNCI Journal of the National Cancer Institute, 2005
- Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older.2002
- Five Years of Tamoxifen--or More?JNCI Journal of the National Cancer Institute, 1996
- Tamoxifen: the Long and Short of ItJNCI Journal of the National Cancer Institute, 1996
- Effects of the antiestrogen tamoxiten on low-density lipoprotein concentrations and oxidation in postmenopausal womenThe American Journal of Cardiology, 1995
- Effects of Tamoxifen on Cardiovascular Risk Factors in Postmenopausal WomenAnnals of Internal Medicine, 1991
- Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee.BMJ, 1991